Can we foresee pharmaceutical markets dominated by biosimilars in future?
Image credit: https://consultqd.clevelandclinic.org/generics-and-biosimilars-in-multiple-sclerosis-navigating-a-new-therapy-landscape/
Konstantinidou, S., Papaspiliou, A., Kokkotou, E."Current and future roles of biosimilars in oncology practice (Review)". Oncology Letters 19.1 (2020): 45-51.
Kim, HoUng et al. “The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.” Drugs vol. 80,2 (2020): 99-113. doi:10.1007/s40265-020-01256-5
Questions first: But why are they different if they have the same clinical properties?
no easy entry, as everything new
Biosimilars: what clinicians should know. 2012, 120 (26):5111-7 Blood
I imagine a bit of patients resistance
 E. Dubé, M. Vivion, and N. E. MacDonald, “Vaccine hesitancy, vaccine refusal and the anti-vaccine movement: Influence, impact and implications,” Expert Review of Vaccines. 2014.